Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224790 | 0.95 | LMNA (0.44) | LMNAMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL3226875 | 0.93 | LMNA (0.43) | LMNAMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL3216282 | 0.91 | LMNA (0.42) | LMNAMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL3201501 | 0.89 | LMNA (0.41) | LMNAMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL3210249 | 0.89 | MAPT (0.44) | LMNAMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL3213825 | 0.86 | LMNA (0.42) | LMNAMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL297406 | 0.86 | MAPT (0.51) | LMNAMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL3215108 | 0.86 | MAPT (0.44) | LMNAMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL3205415 | 0.84 | MAPT (0.41) | LMNAMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL3709143 | 0.84 | MAPT (0.43) | LMNAMAPTMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060293311-A1 | e.g. 1 N2-(4-Aminosulphonylphenyl)-N4-(3-cyanomethoxy-4,5-dimethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | RIGEL PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | claimed |
| EP-2120556-B1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-8389766-B2 | Insecticidal compounds | SYNGENTA CROP PROTECTION LLC (US) | 2013-03-05 | — | — | US | disclosed |
| US-8247594-B2 | Insecticidal compounds | SYNGENTA CROP PROTECTION LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100130601-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100056639-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| EP-2120556-A1 | INSECTICIDAL COMPOUNDS | Syngeta Participations AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| EP-2114161-A1 | INSECTICIDAL COMPOUNDS | Syngeta Participations AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7491732-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| WO-2008107091-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008074427-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-20060293311-A1 | e.g. 1 N2-(4-Aminosulphonylphenyl)-N4-(3-cyanomethoxy-4,5-dimethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | RIGEL PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130601-A1 | INSECTICIDAL COMPOUNDS | ACHE, NIT2, CHRM1 | LMNA 1069/4885MAPT 4101/4885MEN1 885/4885 |
| US-20060293311-A1 | e.g. 1 N2-(4-Aminosulphonylphenyl)-N4-(3-cyanomethoxy-4,5-dimethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | JAK3, JAK1, JAK2 | LMNA 4696/4885MAPT 4206/4885MEN1 2075/4885 |
| US-20100056639-A1 | INSECTICIDAL COMPOUNDS | ACHE, CHRM1, NIT2 | LMNA 899/4885MAPT 3612/4885MEN1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.